WuXi Biologics (Cayman) Inc.
2269
Rangering i aksjer
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Aksjekurs
$5.77
Markedsverdi
$23.74B
Endring (1 dag)
-8.38%
Endring (1 år)
25.13%
Land
CN
Handel WuXi Biologics (Cayman) Inc. (2269)
Kategori
Healthcare
Inntekter for WuXi Biologics (Cayman) Inc. (2269)
Inntekter i Oct 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til WuXi Biologics (Cayman) Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for WuXi Biologics (Cayman) Inc. fra 2014 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $3.11B | 21.73% |
| 2024 | $2.56B | 6.32% |
| 2023 | $2.41B | 8.72% |
| 2022 | $2.21B | 36.72% |
| 2021 | $1.62B | 88.45% |
| 2020 | $859.12M | 50.17% |
| 2019 | $572.10M | 55.27% |
| 2018 | $368.45M | 48.08% |
| 2017 | $248.81M | 74.67% |
| 2016 | $142.45M | 66.06% |
| 2015 | $85.78M | 60.11% |
| 2014 | $53.58M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
